Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody

doi: 10.1007/s00262-021-02900-z

Figure Lengend Snippet: Correlation between TCR and BCR repertoire diversity. a The diversity of TCR or BCR repertoire was evaluated using two different methods, S–W index and invSimp index, before and after anti-PD-1 treatment. The correlation between the TCR and BCR diversity before and after treatment as well as that between post-treatment changes in TCR and BCR diversity was statistically analyzed by Spearman’s rank correlation coefficient. Each dot indicates an individual patient. A solid line with gray band shows linear correlation with 95% confidence intervals. For invSimp index, double logarithmic scaling plot was used before and after treatment, and log10 fold change values were used for the post-treatment changes. b The frequencies of TCR and BCR clones that increased by more than 0.1% (Diff 0.1%) or by more than twofold or tenfold after treatment were assessed and compared. Statistical significances were tested by paired Wilcoxon rank sum test

Article Snippet: Next-generation sequencing analysis of TCR beta chain and BCR IgG heavy chain was performed using an unbiased TCR/BCR repertoire analysis technology developed by Repertoire Genesis Inc. (Osaka, Japan).

Techniques: Clone Assay

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody

doi: 10.1007/s00262-021-02900-z

Figure Lengend Snippet: No significant association between the TCR or BCR repertoire diversity and antitumor response in all the enrolled patients with NSCLC. TCR or BCR repertoire diversity before treatment and their post-treatment changes was compared between the responders (PR; n = 13) and non-responders (SD or PD; n = 17) in all the enrolled patients with NSCLC (n = 30). Statistical significances were tested using the unpaired Wilcoxon rank sum test

Article Snippet: Next-generation sequencing analysis of TCR beta chain and BCR IgG heavy chain was performed using an unbiased TCR/BCR repertoire analysis technology developed by Repertoire Genesis Inc. (Osaka, Japan).

Techniques:

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody

doi: 10.1007/s00262-021-02900-z

Figure Lengend Snippet: Significant association between the TCR or BCR repertoire diversity and antitumor response in the patient subset without EGFR/ALK mutation a TCR or BCR repertoire diversity before treatment and their post-treatment changes were compared between the responders (PR; n = 8) and non-responders (SD or PD; n = 12) in the subset without EGFR/ALK mutation (n = 20). b The frequencies occupied by top 10, 30 and 50 TCR or BCR clones before treatment and their post-treatment changes were compared between the responders (PR; n = 8) and non-responders (SD or PD; n = 12) in the subset without EGFR/ALK mutation (n = 20). c TCR or BCR repertoire diversity before treatment and their post-treatment changes were compared between the responders (PR; n = 5) and non-responders (SD or PD; n = 5) in the subset with EGFR/ALK mutation (n = 10). Statistical significances were tested using the unpaired Wilcoxon rank sum test

Article Snippet: Next-generation sequencing analysis of TCR beta chain and BCR IgG heavy chain was performed using an unbiased TCR/BCR repertoire analysis technology developed by Repertoire Genesis Inc. (Osaka, Japan).

Techniques: Mutagenesis, Clone Assay

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody

doi: 10.1007/s00262-021-02900-z

Figure Lengend Snippet: Significant association between the TCR or BCR repertoire diversity and AE occurrence in the patient subset without EGFR/ALK mutation. a The number of AEs was compared between the responders (PR; n = 8) and non-responders (SD or PD; n = 12) in the subset without EGFR/ALK mutation (n = 20). b TCR or BCR repertoire diversity before treatment and their post-treatment changes in the subset without EGFR/ALK mutation were compared between the patients with (n = 13) and without (n = 7) AEs. Statistical significances were tested using the unpaired Wilcoxon rank sum test

Article Snippet: Next-generation sequencing analysis of TCR beta chain and BCR IgG heavy chain was performed using an unbiased TCR/BCR repertoire analysis technology developed by Repertoire Genesis Inc. (Osaka, Japan).

Techniques: Mutagenesis

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody

doi: 10.1007/s00262-021-02900-z

Figure Lengend Snippet: Difference in the clinical significance of the TCR or BCR repertoire diversity between patients with and without EGFR/ALK mutation. a Post-treatment changes in TCR (upper) and BCR (lower) clonality as well as antitumor responses or AE occurrence were shown in each patient in the subset with (Mut, n = 10) and without (WT, n = 20) EGFR/ALK mutation. The clonality index was calculated as [1—the normalized S–W index]. Each vertical bar indicates an individual patient arranged in the order of post-treatment change of the clonality index (ΔClonality). b All the enrolled patients (n = 30) were divided into two groups based on the median value of post-treatment changes in the TCR repertoire diversity (evaluated by invSimp index). Kaplan–Meier plots of PFS for low and high groups were shown. The difference was evaluated statistically using the Cox proportional hazard model, and hazard ratio (HR), 95% confidence interval (95%CI) and P value were shown. c Patients without EGFR/ALK mutation (n = 20) were divided into two groups based on the median value of post-treatment changes in the TCR repertoire diversity (evaluated by invSimp index). Kaplan–Meier plots of PFS for low and high groups were shown. The difference was evaluated statistically using the Cox proportional hazard model, and HR, 95% CI and P value were shown. d Patients with EGFR/ALK mutation (n = 10) were divided into two groups based on the median value of post-treatment changes in the TCR repertoire diversity (evaluated by invSimp index). Kaplan–Meier plots of PFS for low and high groups were shown. The difference was evaluated statistically using the Cox proportional hazard model, and HR, 95% CI and P value were shown. e Patients without EGFR/ALK mutation (n = 20) were divided into two groups based on the median value of post-treatment changes in the BCR repertoire diversity (evaluated by S–W index). Kaplan–Meier plots of PFS for low and high groups were shown. The difference was evaluated statistically by the Cox proportional hazard model, and HR, 95% CI and P value were shown

Article Snippet: Next-generation sequencing analysis of TCR beta chain and BCR IgG heavy chain was performed using an unbiased TCR/BCR repertoire analysis technology developed by Repertoire Genesis Inc. (Osaka, Japan).

Techniques: Mutagenesis

Journal: International Journal of Molecular Sciences

Article Title: Type IVb Hypersensitivity Reaction in the Novel Murine Model of Palladium–Induced Intraoral Allergic Contact Mucositis

doi: 10.3390/ijms24043137

Figure Lengend Snippet: TCR repertoire analysis of the TRA and TRB in ICM and ACM mice. The NGS–based TCR repertoire analysis was performed on the OM and Ly of ICM and ACM mice on day 5 following the challenge. ( A ) Combining TRAV or TRBV on the X –axis and TRAJ or TRBJ on the Z –axis, with the frequency (percentage) of each clone on the Y –axis, 3D images depict the TCR repertoire ( n = 3, average). ( B ) Shannon Diversity Index is shown in the ACM and ICM, OM and Ly, and TRA and TRB ( n = 3). Statistical significance was tested by the Mann–Whitney U test (* p < 0.05).

Article Snippet: NGS was used to perform a TCR repertoire analysis developed by Repertoire Genesis Inc. (Repertoire Genesis Inc., Osaka, Japan [ ]).

Techniques: MANN-WHITNEY